Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy | Zendy

P Jaquet | Zendy; Ginette Gunz | Zendy; Alexandru Saveanu | Zendy; H. Dufour | Zendy; John E. Taylor | Zendy; Jesse Z. Dong | Zendy; S. Kim | Zendy; J. P. Moreau | Zendy; A Enjalbert | Zendy; Michael D. Culler | Zendy

Open Access

Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy

Author(s) -

P Jaquet,

Ginette Gunz,

Alexandru Saveanu,

H. Dufour,

John E. Taylor,

Jesse Z. Dong,

S. Kim,

J. P. Moreau,

A Enjalbert,

Michael D. Culler

Publication year - 2005

Publication title -

european journal of endocrinology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.897

H-Index - 148

eISSN - 1479-683X

pISSN - 0804-4643

DOI - 10.1530/eje.1.01950

Subject(s) - somatostatin receptor 2 , somatostatin , somatostatin receptor , endocrinology , medicine , prolactin , octreotide , chemistry , receptor , dopamine , somatostatin receptor 1 , lanreotide , biology , acromegaly , hormone , growth hormone

This study compared the potency of a somatostatin receptor (sstr)2-sstr5 analog, BIM-23244, of an sstr2-dopamine D2 receptor (sstr2-DAD2) molecule, BIM-23A387 and of new somatostatin-dopamine chimeric molecules with differing, enhanced affinities for sstr2, sstr5 and DAD2, BIM-23A758, BIM-23A760 and BIM-23A761, to suppress GH and prolactin (PRL) from 18 human GH adenomas that are partially responsive to octreotide or lanreotide.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research